In this study, Chinese scientists working at Lerner Research Institute at the Cleveland Clinic in Cleveland, Ohio, found that mice exposed to glyphosate exhibit multiple blood and plasma abnormalities and damage to bodily organs. They also discovered that exposure to glyphosate induced in the mice a biochemical mechanism that is known to play a role in the development of two types of blood cancers: multiple myeloma (MM) and B-cell lymphoma, which accounts for approximately 90% of non-Hodgkin lymphoma (NHL).
It is one thing to find a significant association between a toxic chemical and a disease, such as the link found in this study between glyphosate exposure and kidney and liver damage. It takes additional evidence to move from there to a conclusion that there is a causative relationship at work—to say the toxin is causing the disease.
To establish causation, scientists study the effects of the toxin in animals that have biological similarities to humans. They look for changes at the cellular and molecular level that might reveal the biological pathways that lead from toxin exposure to the appearance of the disease.
“We uncover a B cell-specific mutational mechanism for glyphosate exposure that increases MM and NHL risk, providing a molecular basis for human epidemiological findings.” – Lei Wang et al. See study details below.
Unlike prior mouse glyphosate carcinogenicity studies, the Wang authors used a mouse strain that is “widely regarded as the best animal model for MM.”
Their study found that exposure to glyphosate activates a key mechanism known to play a role in the development of non-Hodgkin lymphoma and multiple myeloma. Activation-induced cytidine deaminase (also known as AID) is an enzyme that creates mutations in DNA. It does this by actually altering the base pairs that form the “stair steps” in the DNA double-helix ladder. A guanine-cytosine pairing might be converted to an adenine-thymine pair. AID can result in multiple DNA mutations, some occurring when DNA repair mechanisms are engaged.
AID can produce beneficial results for the immune system, but it can also lead to B-cell lymphoma. Wang et al found that glyphosate exposure caused an increase in the production of AID in the spleen and bone marrow in the study mice. AID, they write, “is a B cell-specific genome mutator and a key pathogenic player in both MM and B cell lymphoma.”
“Our data disclose, for the first time, that glyphosate elicits a B cell-specific mutational mechanism of action in promoting carcinogenesis, as well as offering experimental evidence to support the epidemiologic finding regarding its tissue specificity in carcinogenesis (i.e., only increasing the risk for MM and NHL)." – Lei Wang et al. See study details below.
The authors of this study make a very important observation related to causality. While previous studies have revealed several mechanisms by which glyphosate can induce DNA damage, they “failed to explain why glyphosate is only positively associated with MM and NHL.” The discovery of a mechanism that is specifically tied to the two cancers most associated with glyphosate offers strong evidence that glyphosate is causing these diseases.
It should be noted that both of the plaintiffs in the most recent Roundup trial, Alva and Alberta Pilliod, got B-cell lymphoma after using Roundup.
The researchers also found that exposure to glyphosate damaged several organs and produced blood abnormalities in the mice that mirror conditions that precede or coincide with multiple myeloma and NHL.
The full study is available online.
Summary Information
Title
Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice
Authors
Lei Wang1,2, Qipan Deng1, Hui Hu1,3, Ming Liu1,4, Zhaojian Gong1,5, Shanshan Zhang1,6, Zijun Y. Xu-Monette7, Zhongxin Lu3, Ken H. Young7, Xiaodong Ma1,8,9, and Yong Li1
Journal
Journal of Hematology & Oncology (2019),12(1):70
Funding
YL is supported in part by NIH R01 grants (CA138688 and CA177810); LW is supported by National Natural Science Foundation of China (NO. 31500326) and Natural Science Foundation of Guangdong Province of China (NO. 2017A030313194).
Contact Wisner Baum today to get started with our team.
"Wisner Baum gave exceptional attention to all aspects of the case, detailed inquiry, and tenacious overview of all the information submitted. The paralegals are efficient and diligent. I was completely surprised to find an empathic personal message to take care of my own health during the challenging time of being a full-time caretaker.*"
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s. R. Brent Wisner served as co-lead trial attorney for the Pilliods, delivering the opening and closing statements and cross-examining several of Monsanto’s experts. Wisner Baum managing shareholder, Michael Baum and attorney Pedram Esfandiary also served on the trial team in the Pilliod case.
The judge later reduced their award to $87M. Monsanto appealed the Pilliod’s verdict which the California Court of Appeal for the First Appellate District denied on August 9, 2021. Monsanto then requested the California Supreme Court review the appeal’s court decision, which the court denied on Nov. 17, 2021. Monsanto (Bayer) then submitted a petition for a writ of certiorari with the U.S. Supreme Court which SCOTUS denied on June 27, 2022, allowing the final judgment of $87M to remain intact.
$289.2 million jury verdict in Monsanto Roundup trial
Wisner Baum co-represented Dewayne “Lee” Johnson in the first Roundup cancer lawsuit to proceed to trial. On Aug. 10, 2018, a San Francisco jury ordered Monsanto to pay $39.25 million in compensatory damages and $250 million in punitive damages to Mr. Johnson, a former groundskeeper who alleged exposure to Monsanto’s herbicides caused him to develop terminal non-Hodgkin lymphoma.
Months after the jury verdict, the judge overseeing the trial reduced the punitive damages to $39.25 million. Mr. Johnson decided to accept the remittitur, bringing the adjusted amount awarded to Mr. Johnson $78.5 million.
Monsanto (Bayer) appealed the verdict and Johnson cross appealed. On July 20, 2020, the First Circuit Court of Appeals upheld the verdict against Monsanto but reduced Mr. Johnson’s award to $20.5 million. The company chose not to take the case to the U.S. Supreme Court, ending the litigation.
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.